Search

Your search keyword '"Steinberg, Gary D."' showing total 1,032 results
Start Over Author "Steinberg, Gary D."
1,032 results on '"Steinberg, Gary D."'

1. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D. more...

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

3. Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D. more...

Published
2024
Full Text
View/download PDF

4. Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D. more...

Published
2024
Full Text
View/download PDF

6. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer

Author

Gore, John L., Wolff, Erika M., Comstock, Bryan A., Follmer, Kristin M., Nash, Michael G., Basu, Anirban, Chisolm, Stephanie, MacLean, Douglas B., Lee, Jenney R., Lotan, Yair, Porten, Sima P., Steinberg, Gary D., Chang, Sam S., Gilbert, Scott M., Kessler, Larry G., and Smith, Angela B. more...

Published
2023
Full Text
View/download PDF

9. Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive bladder cancer: Results from a prospective multi-center registry.

Author

Ghoreifi, Alireza, Konety, Badrinath R., Pohar, Kamal S., Holzbeierlein, Jeffrey, Taylor III, John Arthur, Kates, Max, Willard, Brian, Taylor, Jennifer M., Liao, Joseph C., Kaimakliotis, Hristos Z., Porten, Sima P., Steinberg, Gary D., Tyson, Mark, Lotan, Yair, and Daneshmand, Siamak more...

Published
2025
Full Text
View/download PDF

10. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients

Author

Williams, Stephen B, Kamat, Ashish M, Chamie, Karim, Froehner, Michael, Wirth, Manfred P, Wiklund, Peter N, Black, Peter C, Steinberg, Gary D, Boorjian, Stephen A, Daneshmand, Sia, Goebell, Peter J, Pohar, Kamal S, Shariat, Shahrokh F, and Thalmann, George N more...

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Patient Safety, 7.3 Management and decision making, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Comorbidity, Competing risks, Bladder cancer, Models, Indices, Survival, Mortality, Review, Clinical sciences, Oncology and carcinogenesis
Abstract

ContextRadical cystectomy continues to be associated with a significant risk of morbidity and all-cause mortality (ACM). Practice pattern data demonstrating underuse of surgery for patients with muscle-invasive and high-risk non-muscle invasive bladder cancer (BC) have been linked to the advanced age and higher comorbidity status of such patients, which suggests that rates of ACM as well as cancer-specific mortality should be incorporated into patient counseling and guideline recommendations.ObjectiveTo review the literature on risk assessment tools for preoperative comorbidity in BC that may aid in treatment decision-making.Evidence acquisitionA systematic search was conducted using Ovid and Medline according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2017 reporting on comorbidity risk assessment (CRA) tools for BC. Prospective and retrospective studies were included.Evidence synthesisThere are no published randomized control trials comparing CRA tools for BC. Patients undergoing radical cystectomy with combined high-risk comorbidity and performance scores may face up to a sevenfold greater risk of other-cause mortality compared to those with low scores. The Charlson Comorbidity Index is one of the most widely studied indices for 90-d perioperative mortality and overall and cancer-specific survival, with an area under the receiver operating characteristic curve of up to 0.810. Prospective studies of CRA tools for BC have consistently shown that patients with higher comorbidity have worse outcomes. While not specific for BC, comorbidity indices provide useful assessment of competing risks. Competing-risks assessment tools are lacking, with limited studies assessing the impact of these tools on treatment decision-making by patients and providers. We provide the impetus for incorporation of comorbidity risks into practice guidelines when discussing treatment options with patients.ConclusionsCRA tools should be incorporated into preoperative treatment counseling and the assessment of postoperative outcomes. While retrospective evidence supports the use of CRA tools for BC, further comparative studies evaluating the effectiveness of these tools and identifying the patients most likely to benefit from a treatment according to competing-risks assessment are needed.Patient summaryIn this review we explored the clinical evidence for comorbidity risk assessment tools in bladder cancer. We found evidence to support incorporation of comorbidity risks into practice guidelines when discussing treatment options with patients. more...

Published
2018

11. Interruptions in bladder cancer care during the COVID-19 public health emergency

Author

Gore, John L., Follmer, Kristin, Reynolds, Jason, Nash, Michael, Anderson, Christopher B., Catto, James W.F., Chamie, Karim, Daneshmand, Siamak, Dickstein, Rian, Garg, Tullika, Gilbert, Scott M., Guzzo, Thomas J., Kamat, Ashish M., Kates, Max R., Lane, Brian R., Lotan, Yair, Mansour, Ahmed M., Master, Viraj A., Montgomery, Jeffrey S., Morris, David S., Nepple, Kenneth G., O'Neil, Brock B., Patel, Sanjay, Pohar, Kamal, Porten, Sima P., Riggs, Stephen B., Sankin, Alexander, Scarpato, Kristen R., Shore, Neal D., Steinberg, Gary D., Strope, Seth A., Taylor, Jennifer M., Comstock, Bryan A., Kessler, Larry G., Wolff, Erika M., and Smith, Angela B. more...

Published
2024
Full Text
View/download PDF

15. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis

Author

Williams, Stephen B., Cumberbatch, Marcus G.K., Kamat, Ashish M., Jubber, Ibrahim, Kerr, Preston S., McGrath, John S., Djaladat, Hooman, Collins, Justin W., Packiam, Vignesh T., Steinberg, Gary D., Lee, Eugene, Kassouf, Wassim, Black, Peter C., Cerantola, Yannick, Catto, James W.F., and Daneshmand, Siamak more...

Published
2020
Full Text
View/download PDF

19. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL

Author

Boorjian, Stephen A., primary, Narayan, Vikram M., additional, Konety, Badrinath R., additional, Master, Viraj A., additional, Shore, Neal D., additional, Kamat, Ashish M., additional, Bivalacqua, Trinity J., additional, Kates, Max R., additional, Montgomery, Jeffrey S., additional, Lerner, Seth P., additional, Crispen, Paul L., additional, Steinberg, Gary D., additional, Agarwal, Piyush K., additional, Schuckman, Anne K., additional, Svatek, Robert S., additional, Lane, Brian R., additional, Karsh, Lawrence I., additional, Bjurlin, Marc A., additional, Brown, Gordon A., additional, Lotan, Yair, additional, Inman, Brant A., additional, Williams, Michael B., additional, Cookson, Michael S., additional, Chang, Sam S., additional, Kim, Eric H., additional, Sankin, Alexander I., additional, Rehm, Dorte, additional, Jakobsen, Jørn S., additional, Juul, Kristian, additional, and Dinney, Colin P. N., additional more...

Published
2024
Full Text
View/download PDF

21. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL

Author

Boorjian, Stephen A., primary, Narayan, Vikram M., additional, Master, Viraj A., additional, Konety, Badrinath R., additional, Shore, Neal D., additional, Kamat, Ashish M., additional, Dinney, Colin P.N., additional, Bivalacqua, Trinity J., additional, Kates, Max R., additional, Montgomery, Jeffrey S., additional, Lerner, Seth P., additional, Crispen, Paul L., additional, Steinberg, Gary D., additional, Agarwal, Piyush K., additional, Schuckman, Anne K., additional, Svatek, Robert S., additional, Lane, Brian R., additional, Karsh, Lawrence I., additional, Bjurlin, Marc A., additional, Brown, Gordon A., additional, Lotan, Yair, additional, Inman, Brant A., additional, Williams, Michael B., additional, Cookson, Michael S., additional, Chang, Sam S., additional, Kim, Eric H., additional, Sankin, Alexander I., additional, O'Donnell, Michael A., additional, Jakobsen, Jørn S., additional, and Juul, Kristian, additional more...

Published
2024
Full Text
View/download PDF

23. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

Author

Steinberg, Gary D, primary, Shore, Neal D, additional, Redorta, Joan Palou, additional, Galsky, Matthew D, additional, Bedke, Jens, additional, Ku, Ja Hyeon, additional, Kretkowski, Michal, additional, Hu, Hailong, additional, Penkov, Konstantin, additional, Vermette, Jennifer J, additional, Tarazi, Jamal C, additional, Randall, Alison E, additional, Pierce, Kristen J, additional, Saltzstein, Daniel, additional, and Powles, Thomas B, additional more...

Published
2024
Full Text
View/download PDF

25. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.

Author

Narayan, Vikram M., Boorjian, Stephen A., Alemozaffar, Mehrdad, Konety, Badrinath R., Shore, Neal D., Gomella, Leonard G., Kamat, Ashish M., Bivalacqua, Trinity J., Montgomery, Jeffrey S., Lerner, Seth P., Busby, Joseph E., Poch, Michael, Crispen, Paul L., Steinberg, Gary D., Schuckman, Anne K., Downs, Tracy M., Mashni Jr, Joseph, Lane, Brian R., Guzzo, Thomas J., and Bratslavsky, Gennady more...

Subjects
NON-muscle invasive bladder cancer, CLINICAL trials, INTRAVESICAL administration, BLADDER cancer, CANCER genes
Abstract

Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector–based gene therapy for bacillus Calmette-Guérin (BCG)–unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up. Materials and Methods: This open-label phase 3 trial (NCT02773849) enrolled patients with BCG-unresponsive nonmuscle-invasive bladder cancer in 2 cohorts: CIS ± Ta/T1 (CIS; n = 107) and Ta/T1 without CIS (Ta/T1 cohort; n = 50). Patients received 75 mL (3 × 1011 vp/mL) nadofaragene firadenovec intravesically once every 3 months with cystoscopy and cytology assessments, with continued treatment offered to those remaining high grade recurrence–free (HGRF). Results: One hundred fifty-seven patients were enrolled from 33 US sites (n = 151 included in efficacy analyses). Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months. Of patients with CIS 5.8% (95% CI 2.2-12.2) were HGRF at month 57, and 15% (95% CI 6.1-27.8) of patients with high-grade Ta/T1 were HGRF at month 57. Kaplan-Meier–estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively. Only 5 patients (4 with CIS and 1 with Ta/T1) experienced clinical progression to muscle-invasive disease. Conclusions: At 60 months, nadofaragene firadenovec-vncg allowed bladder preservation in nearly half of the patients and proved to be a safe option for BCG-unresponsive nonmuscle-invasive bladder cancer. [ABSTRACT FROM AUTHOR] more...

Published
2024
Full Text
View/download PDF

28. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Author

Packiam, Vignesh T., Lamm, Donald L., Barocas, Daniel A., Trainer, Andrew, Fand, Benjamin, Davis, Ronald L., III, Clark, William, Kroeger, Michael, Dumbadze, Igor, Chamie, Karim, Kader, A. Karim, Curran, Dominic, Gutheil, John, Kuan, Arthur, Yeung, Alex W., and Steinberg, Gary D. more...

Published
2018
Full Text
View/download PDF

30. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer

Author

Harshman, Lauren C., Tripathi, Abhishek, Kaag, Matthew, Efstathiou, Jason A., Apolo, Andrea B., Hoffman-Censits, Jean H., Stadler, Walter M., Yu, Evan Y., Bochner, Bernard H., Skinner, Eila C., Downs, Tracy, Kiltie, Anne E., Bajorin, Dean F., Guru, Khurshid, Shipley, William U., Steinberg, Gary D., Hahn, Noah M., and Sridhar, Srikala S. more...

Published
2018
Full Text
View/download PDF

37. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

Author

Kamat, Ashish M., primary, Apolo, Andrea B., additional, Babjuk, Marek, additional, Bivalacqua, Trinity J., additional, Black, Peter C., additional, Buckley, Roger, additional, Campbell, Matthew T., additional, Compérat, Eva, additional, Efstathiou, Jason A., additional, Grivas, Petros, additional, Gupta, Shilpa, additional, Kurtz, Neil J., additional, Lamm, Donald, additional, Lerner, Seth P., additional, Li, Roger, additional, McConkey, David J., additional, Palou Redorta, Joan, additional, Powles, Thomas, additional, Psutka, Sarah P., additional, Shore, Neal, additional, Steinberg, Gary D., additional, Sylvester, Richard, additional, Witjes, J. Alfred, additional, and Galsky, Matthew D., additional more...

Published
2023
Full Text
View/download PDF

38. Interruptions in bladder cancer care during the COVID-19 public health emergency

Author

Gore, John L., primary, Follmer, Kristin, additional, Reynolds, Jason, additional, Nash, Michael, additional, Anderson, Christopher B., additional, Catto, James W.F., additional, Chamie, Karim, additional, Daneshmand, Siamak, additional, Dickstein, Rian, additional, Garg, Tullika, additional, Gilbert, Scott M., additional, Guzzo, Thomas J., additional, Kamat, Ashish M., additional, Kates, Max R., additional, Lane, Brian R., additional, Lotan, Yair, additional, Mansour, Ahmed M., additional, Master, Viraj A., additional, Montgomery, Jeffrey S., additional, Morris, David S., additional, Nepple, Kenneth G., additional, O'Neil, Brock B., additional, Patel, Sanjay, additional, Pohar, Kamal, additional, Porten, Sima P., additional, Riggs, Stephen B., additional, Sankin, Alexander, additional, Scarpato, Kristen R., additional, Shore, Neal D., additional, Steinberg, Gary D., additional, Strope, Seth A., additional, Taylor, Jennifer M., additional, Comstock, Bryan A., additional, Kessler, Larry G., additional, Wolff, Erika M., additional, and Smith, Angela B., additional more...

Published
2023
Full Text
View/download PDF

39. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Author

Akbani, Rehan, Al-Ahmadie, Hikmat, Albert, Monique, Alexopoulou, Iakovina, Ally, Adrian, Antic, Tatjana, Aron, Manju, Balasundaram, Miruna, Bartlett, John, Baylin, Stephen B., Beaver, Allison, Bellmunt, Joaquim, Birol, Inanc, Boice, Lori, Bootwalla, Moiz S., Bowen, Jay, Bowlby, Reanne, Brooks, Denise, Broom, Bradley M., Bshara, Wiam, Bullman, Susan, Burks, Eric, Cárcano, Flavio M., Carlsen, Rebecca, Carvalho, Benilton S., Carvalho, Andre L., Castle, Eric P., Castro, Mauro A.A., Castro, Patricia, Catto, James W., Chagas, Vinicius S., Cherniack, Andrew D., Chesla, David W., Choo, Caleb, Chuah, Eric, Chudamani, Sudha, Cortessis, Victoria K., Cottingham, Sandra L., Crain, Daniel, Curley, Erin, Czerniak, Bogdan A., Daneshmand, Siamak, Demchok, John A., Dhalla, Noreen, Djaladat, Hooman, Eckman, John, Egea, Sophie C., Engel, Jay, Felau, Ina, Ferguson, Martin L., Gardner, Johanna, Gastier-Foster, Julie M., Gerken, Mark, Getz, Gad, Gibb, Ewan A., Gomez-Fernandez, Carmen R., Gordenin, Dmitry A., Guo, Guangwu, Hansel, Donna E., Harr, Jodi, Hartmann, Arndt, Herbert, Lynn M., Hinoue, Toshinori, Ho, Thai H., Hoadley, Katherine A., Holt, Robert A., Hutter, Carolyn M., Jones, Steven J.M., Jorda, Merce, Kahnoski, Richard J., Kanchi, Rupa S., Kasaian, Katayoon, Kim, Jaegil, Klimczak, Leszek J., Kwiatkowski, David J., Lai, Phillip H., Laird, Peter W., Lane, Brian R., Leraas, Kristen M., Lerner, Seth P., Lichtenberg, Tara M., Liu, Jia, Lolla, Laxmi, Lotan, Yair, Lu, Yiling, Lucchesi, Fabiano R., Ma, Yussanne, Machado, Roberto D., Maglinte, Dennis T., Mallery, David, Marra, Marco A., Martin, Sue E., Mayo, Michael, McConkey, David J., Meraney, Anoop, Meyerson, Matthew, Mills, Gordon B., Moinzadeh, Alireza, Moore, Richard A., Mora Pinero, Edna M., Morris, Scott, Morrison, Carl, Mungall, Karen L., Mungall, Andrew J., Myers, Jerome B., Naresh, Rashi, O'Donnell, Peter H., Ojesina, Akinyemi I., Parekh, Dipen J., Parfitt, Jeremy, Paulauskis, Joseph D., Sekhar Pedamallu, Chandra, Penny, Robert J., Pihl, Todd, Porten, Sima, Quintero-Aguilo, Mario E., Ramirez, Nilsa C., Rathmell, W. Kimryn, Reuter, Victor E., Rieger-Christ, Kimberly, Robertson, A. Gordon, Sadeghi, Sara, Saller, Charles, Salner, Andrew, Sanchez-Vega, Francisco, Sandusky, George, Scapulatempo-Neto, Cristovam, Schein, Jacqueline E., Schuckman, Anne K., Schultz, Nikolaus, Shelton, Candace, Shelton, Troy, Shukla, Sachet A., Simko, Jeff, Singh, Parminder, Sipahimalani, Payal, Smith, Norm D., Sofia, Heidi J., Sorcini, Andrea, Stanton, Melissa L., Steinberg, Gary D., Stoehr, Robert, Su, Xiaoping, Sullivan, Travis, Sun, Qiang, Tam, Angela, Tarnuzzer, Roy, Tarvin, Katherine, Taubert, Helge, Thiessen, Nina, Thorne, Leigh, Tse, Kane, Tucker, Kelinda, Van Den Berg, David J., van Kessel, Kim E., Wach, Sven, Wan, Yunhu, Wang, Zhining, Weinstein, John N., Weisenberger, Daniel J., Wise, Lisa, Wong, Tina, Wu, Ye, Wu, Catherine J., Yang, Liming, Zach, Leigh Anne, Zenklusen, Jean C., Zhang, Jiashan (Julia), Zhang, Jiexin, Zmuda, Erik, Zwarthoff, Ellen C., de Sa Carvalho, Benilton, Pedamallu, Chandra Sekhar, and Schultz, Nicholaus more...

Published
2017
Full Text
View/download PDF

40. Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach

Author

Lee, Cheryl T., Mohamed, Nihal E., Pisipati, Sailaja, Shah, Qainat N., Agarwal, Piyush K., Downs, Tracy M., Droller, Michael, Gilbert, Scott M., Goltz, Heather H., Hall, Simon J., Hendawi, Mohamed, Hoffman-Censits, Jean, O’Donnell, Michael, Kaag, Matthew, Karsh, Lawrence I., Kassouf, Wassim, Quale, Diane Z., Sagalowsky, Arthur, Steinberg, Gary D., and Latini, David M. more...

Published
2020
Full Text
View/download PDF

41. Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Author

Ladi-Seyedian, Seyedeh-Sanam, Ghoreifi, Alireza, Konety, Badrinath, Pohar, Kamal, Holzbeierlein, Jeffrey M., Taylor, John, Kates, Max, Willard, Brian, Taylor, Jennifer M., Liao, Joseph C., Kaimakliotis, Hristos Z., Porten, Sima P., Steinberg, Gary D., Tyson, Mark D., Lotan, Yair, and Daneshmand, Siamak more...

Subjects
BLADDER tumors, BIOPSY, PREDICTIVE tests, CYSTOSCOPY, AFRICAN Americans, RESEARCH funding, HISPANIC Americans, FISHER exact test, WHITE people, DESCRIPTIVE statistics, RACE, RESEARCH, TRANSURETHRAL resection of bladder, HEALTH outcome assessment, DATA analysis software, SENSITIVITY & specificity (Statistics)
Abstract

Simple Summary: Blue light cystoscopy (BLC) is a technique used to find bladder tumors more effectively. However, its performance across different races remains uncertain. In this study, we looked at how well BLC detects cancer in people of different races. We collected data from patients who had bladder tumor surgeries from 2014 to 2021. Overall, we found that BLC was better at spotting tumors compared to traditional white light cystoscopy (WLC). This was true for most races, especially for Caucasian and Asian patients. When BLC was added to WLC, it increased the detection of cancer by 10%, with the biggest improvement seen in Asian patients. Interestingly, Asian patients had the highest chance of BLC correctly identifying cancer, while Hispanic patients had the best chance of ruling out cancer. This suggests that combining BLC with WLC can improve the detection of bladder cancer irrespective of race. The use of blue light cystoscopy (BLC) has been shown to improve bladder tumor detection. However, data demonstrating the efficacy of BLC across different races are limited. Herein, we aim to evaluate heterogeneity in the characteristics of BLC for the detection of malignant lesions among various races. Clinicopathologic information was collected from patients enrolled in the multi-institutional Cysview® registry (2014–2021) who underwent transurethral resection or biopsy of bladder tumors. Outcome variables included sensitivity and negative and positive predictive values of BLC and white light cystoscopy (WLC) for the detection of malignant lesions among various races. Overall, 2379 separate lesions/tumors were identified from 1292 patients, of whom 1095 (85%) were Caucasian, 96 (7%) were African American, 51 (4%) were Asian, and 50 (4%) were Hispanic. The sensitivity of BLC was higher than that of WLC in the total cohort, as well as in the Caucasian and Asian subgroups. The addition of BLC to WLC increased the detection rate by 10% for any malignant lesion in the total cohort, with the greatest increase in Asian patients (18%). Additionally, the positive predictive value of BLC was highest in Asian patients (94%), while Hispanic patients had the highest negative predictive value (86%). Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC. [ABSTRACT FROM AUTHOR] more...

Published
2024
Full Text
View/download PDF

44. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis

Author

Packiam, Vignesh T., Labbate, Craig V., Boorjian, Stephen A., Tarrell, Robert, Cheville, John C., Avulova, Svetlana, Sharma, Vidit, Tsivian, Matvey, Adamic, Brittany, Mahmoud, Mohammad, Werntz, Ryan P., Smith, Norm D., Karnes, R. Jeffrey, Tollefson, Matthew K., Steinberg, Gary D., and Frank, Igor more...

Published
2021
Full Text
View/download PDF

45. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) Study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer

Author

Gore, John L., primary, Wolff, Erika, additional, Comstock, Bryan A., additional, Follmer, Kristin M., additional, Nash, Michael G., additional, Basu, Anirban, additional, Chisolm, Stephanie, additional, MacLean, Douglas B., additional, Lee, Jenney R., additional, Lotan, Yair, additional, Porten, Sima P., additional, Steinberg, Gary D., additional, Chang, Sam S., additional, Gilbert, Scott M., additional, Kessler, Larry G., additional, Smith, Angela B., additional, and Collaborative, CISTO, additional more...

Published
2023
Full Text
View/download PDF

46. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Author

Chang, Elaine, primary, Hahn, Noah M., additional, Lerner, Seth P., additional, Fallah, Jaleh, additional, Agrawal, Sundeep, additional, Kamat, Ashish M., additional, Bhatnagar, Vishal, additional, Svatek, Robert S., additional, Jaigirdar, Adnan A., additional, Bross, Peter, additional, Shore, Neal, additional, Kates, Max, additional, Sachse, Karen, additional, Brewer, Jamie R., additional, O’Donnell, Michael A., additional, Steinberg, Gary D., additional, Viviano, Charles J., additional, Bloomquist, Erik, additional, Ribal, Maria J., additional, Galsky, Matthew D., additional, Oliver, Richard, additional, Black, Peter C., additional, Al-Ahmadie, Hikmat, additional, Brothers, Kenneth, additional, Pohar, Kamal, additional, Dinney, Colin P., additional, Feng, Zhou, additional, Downs, Tracy M., additional, Porten, Sima P., additional, Smith, Angela B., additional, Bangs, Rick, additional, Psutka, Sarah P., additional, Agarwal, Neeraj, additional, Amiri-Kordestani, Laleh, additional, Suzman, Daniel L., additional, Pazdur, Richard, additional, Kluetz, Paul G., additional, and Weinstock, Chana, additional more...

Published
2023
Full Text
View/download PDF